News & Updates
Filter by Specialty:
Psychotic disorders a potentially modifiable risk factor for dementia
Individuals with nonaffective psychotic disorders appear to have a twofold higher risk of developing subsequent dementia compared with those who do not have such disorders, as reported in a recent study.
Psychotic disorders a potentially modifiable risk factor for dementia
25 Oct 2022
Singaporeans’ affair with Western-style fast food: Unhealthy and possibly deadly
A diet heavy in Western-style fast food is known to make people fat and unhealthy, and a recent study quantifies its toll in an Eastern population, particularly Singaporeans: Frequent intake puts one at risk of developing type 2 diabetes (T2D) and dying from coronary heart disease (CHD).
Singaporeans’ affair with Western-style fast food: Unhealthy and possibly deadly
25 Oct 2022
Brentuximab vedotin-chemo confers OS advantage over bleomycin-containing chemo for advanced HL
In the 6-year follow-up of the ECHELON-1 trial, a combination of the CD30-directed ADC* brentuximab vedotin and a chemotherapy (CT) regimen comprising doxorubicin, vinblastine, and dacarbazine (A+AVD), showed a survival advantage over a combination comprising the same CT regimen plus bleomycin (ABVD) in patients with previously untreated stage III or IV Hodgkin’s lymphoma (HL).
Brentuximab vedotin-chemo confers OS advantage over bleomycin-containing chemo for advanced HL
25 Oct 2022
Hepatitis B vaccine with TLR-9 agonist achieves high protection in people with HIV
Among people living with HIV (PLHIV), immunization with a hepatitis B surface antigen (HBsAg)-based vaccine adjuvanted with a toll-like receptor (TLR)-9 agonist can induce a 100-percent seroprotection rate, according to a study presented at the recently concluded Virtual ID Week 2022.
Hepatitis B vaccine with TLR-9 agonist achieves high protection in people with HIV
25 Oct 2022
Tocilizumab trumps etanercept at suppressing RA joint erosion
Treatment with tocilizumab leads to better suppression of joint erosion progression as compared to etanercept in patients with rheumatoid arthritis (RA), reports a recent study.
Tocilizumab trumps etanercept at suppressing RA joint erosion
25 Oct 2022
Treatment failure risk in older IBD patients higher with vedolizumab vs TNF antagonists
The use of vedolizumab in the treatment of older patients with inflammatory bowel disease (IBD) appears to not only pose a higher risk of treatment failure but also offer no significant safety advantage when compared with tumour necrosis factor (TNF) antagonists, according to a study.
